Biocon Biologics, a subsidiary of Biocon, announced today that it has signed an agreement with Clinton Health Access Initiative (CHAI) to develop advanced cancer therapies for patients in 25 countries in Africa and 5 countries in Asia as part of the Cancer Access Partnership (CAP). According to the announcement, Biocon Biologics aims to offer affordable biosimilars, initially trastuzumab (bTrastuzumab) and pegfilgrastim (bPegfilgrastim), with plans to expand the arrangement to include other biosimilars over time.
Biocon Biologics is the only Indian company to have commercialized three biosimilar products in the U.S. (trastuzumab, pegfilgrastim, and insulin glargine). Its bTrastuzumab product has received regulatory approvals in over 60 countries and has already been commercialized in U.S., EU, Canada, Australia, while its bPegfilgrastim product has received approvals in approximately 40 countries and is also currently commercially available in U.S., EU, Canada and Australia.,
The post Biocon Biologics Expands Access to Biosimilars In Over 30 Countries In Africa and Asia appeared first on Big Molecule Watch.